Veterinary Dermatology Drugs Market Size & Outlook, 2025-2033

Veterinary Dermatology Drugs Market Overview

The global veterinary dermatology drugs market size was valued at USD 9.64 billion in 2024 and is anticipated to grow from USD 10.74 billion in 2025 to reach USD 22.58 billion in 2033, growing at a CAGR of 9.5% during the forecast period (2025–2033). The growth of the market is attributed to increasing pet adoption and animal care.

Key Market Indicators

• North America dominated the veterinary dermatology drugs industry and accounted for a 39.13% share in 2024, driven by pet adoption, spending, disease prevalence, advanced care, and strong stakeholder support.
• Based on drugs, the veterinary antifungal drugs segment dominates, growing at 9.62% CAGR, driven by awareness, accessibility, and demand from companion animals and livestock.
• Based on animal type, the small animal segment dominates, led by dogs, with growth driven by rising pet ownership, protein demand, parasitic diseases, and atopic dermatitis prevalence.
• Based on end user, the veterinary hospital segment leads the market, growing at 9.71% CAGR, driven by rising pharmacies, diagnostics, and comprehensive animal care services.

Market Size & Forecast

• 2024 Market Size: USD 9.64 billion
• 2033 Projected Market Size: USD 22.58 billion
• CAGR (2025–2033): 9.5%
• North America: Largest market in 2024
• Asia Pacific: Fastest-growing region

Animals with chronic diseases, dysfunction, and damage are managed, found, and treated in veterinary dermatology. Veterinarian dermatologists are exceptionally skilled at identifying and treating bacterial, fungal, and viral infectious skin diseases in animals. Many animals worldwide experience severe illnesses, such as skin conditions caused by parasites, dander-related skin disorders, alopecia, intrinsic skin infections, autoimmune skin diseases, mild and dangerous skin cancer, hormonal-related skin conditions, and other internal causes of skin abnormalities. Pets, pet owners, and other animals are benefiting from improvements in medical technology and expanding research resources for veterinary dermatologists to diagnose and treat such severe diseases. As a result, the forecasted growth of the global veterinary dermatology drugs market will be influenced by the increase in veterinary visits. The field of veterinary dermatology covers a wide range of disorders that may affect different species and all domesticated and wild animal species. The primary factors that propel market growth include the rising prevalence of skin diseases in animals and significant investments made by top market players. The market is forecasted to grow due to a trend in which pet owners make more decisions about their pets' care.

To get more insights about this report Download Free Sample Report

Market Growth Factor

Increasing Pet Adoption and Animal Care

Due to the increased public awareness of veterinary care, the market for drugs used in veterinary dermatology has experienced significant growth. It is anticipated that increasing urbanization and the number of pets will impact the market for veterinary dermatology drugs. Atopic dermatitis in animals is becoming more common, which has raised the need for better veterinary medications. The world is becoming more aware of veterinary skin conditions, available treatments, and various government programs to boost farm animal productivity, especially for pet guardians and owners. In addition, the forecasted period will see an increase in the population of companion animals and consumer willingness to pay for their healthcare. The market for veterinary dermatology medications is anticipated to grow at a moderate CAGR. The use of veterinary dermatology drugs has increased due to an increase in pet animal longevity brought on by advancements in diagnostics, increased emphasis on wellness and prevention by veterinarians, and improved nutrition.

Market Restraint

Limited Availability and Knowledge of These Drugs

Many developing and underdeveloped nations lack access to these medications, which may hinder market growth and demand for veterinary dermatology medications. Additionally, despite becoming aware of the adverse effects of such medications, pet owners in many nations still prefer to treat their animals without using medication. Additionally, the market for veterinary dermatology drugs is anticipated to face difficulties due to insufficient knowledge about these medications in many underdeveloped nations. Many nations worldwide imposed strict lockdown restrictions to stop the virus's spread. The distribution of non-essential items like pet medications is prohibited under these restrictions.

Market Opportunity

The Increase in Demand for Animal Antifungals

Mycotic diseases in animals have received much less attention than some common illnesses in humans and animals, such as mycoses. Compared to some common diseases affecting humans and animals, animal mycotic diseases have received less attention. This is abnormal because dermatophytes, one of the earliest disorders in animals to be recognized, act as carriers of infectious diseases in animals. The dermatophytes are thought to be responsible for a sizable portion of human skin diseases transmitted to humans by animals and are known to cause many zoonotic infections. This is unusual because one of the earliest known disorders in animals is dermatophytes acting as carriers of infectious diseases in animals. Several zoonotic infections are caused by dermatophytes, which are also thought to cause 80% of skin diseases that humans contract from animals. However, recent animal medicine and treatment advancements effectively cure such illnesses. Additionally, producers are concentrating on R&D to prevent dermatophytes and associated infections. These innovations will likely draw numerous pet owners to the market for veterinary dermatology medications throughout the anticipated period.

Regional Insights

North America is the most significant shareholder in the global veterinary dermatology drugs market and is expected to grow at a CAGR of 9.12% during the forecast period. The U.S. and Canada are included in the analysis of the veterinary dermatology drugs market in North America. This is due to more people adopting companion animals in developed nations like the United States and Canada. More people are spending more on pet care in this region, boosting the market growth.

Several major players, including Zoetis, Merck & Co., Inc., and Elanco Animal Health, are based in the U.S. and are actively pursuing strategic initiatives to expand their market presence. At the same time, regulatory bodies like the FDA are approving new therapies, broadening treatment options for veterinarians and pet owners. Furthermore, collaborations between veterinary drug makers and multinational corporations are driving faster development and wider distribution of dermatology products.

• In September 2024, the FDA approved Elanco’s Zenrelia™ (ilunocitinib tablets), a once-daily oral Janus kinase (JAK) inhibitor to control pruritus and atopic dermatitis in dogs aged 12 months and older. Zenrelia launched in the US and gained EU and UK approval in 2025, offering comparable efficacy to Apoquel, fast relief from itching, and reduced risk of rebound symptomswith a single daily dose.

The market is expanding, but the high prevalence of pruritus, sores, alopecia, masses, eruptions, scales, seborrhea, pustules, and draining tracts in companion animals is driving this. Another factor that favorably affects the market is the growing technology in veterinary medicine, which has increased the lifespan of veterinary animals. The region's growth is fueled by increased measures taken by the public and private sectors, rising pet care costs, and an increase in significant stakeholders. Additionally, zoonotic disease prevalence is likely to support market expansion.

Asia Pacific Market Trends

Asia Pacific is expected to grow at a CAGR of 9.96% during the forecast period. China, India, Japan, Australia, and the rest of Asia-Pacific are all included in the Asia-Pacific veterinary dermatology drugs market analysis. Increased pet ownership and technological advancements in the drug development process are the two main drivers of the market's expansion due to factors like the rising demand for veterinary dermatology medications and the gradually growing awareness of the products' accessibility in developing nations like India and China.

Additionally, the fact that many significant market players, including Elanco, have manufacturing facilities in Asia Pacific helps the region's growth. This results from both more excellent knowledge of veterinary treatment options and the location of Elanco's manufacturing facilities, which produce veterinary dermatology medications. This is one of the critical elements affecting the APAC market for veterinary dermatology medications.

Latin America Market Trends

The Latin American veterinary dermatology drug sector is growing due to rising awareness of pet healthcare and an increase in dermatological conditions in animals. Key growth drivers include the burgeoning pet population, heightened adoption of veterinary skin treatments, and innovations in drug formulations. The need for effective therapies for medical inflictions such as atopic dermatitis, allergies, and parasitic infections particularly influences market demand. Brazil, Mexico, and Argentina are major contributors to this market expansion, focusing on innovative therapies and cost-effective solutions for pet owners.

In Brazil, the veterinary dermatology market is witnessing steady growth, propelled by increasing attention to animal wellness, rising pet ownership, and a surge in skin-related disorders among companion animals. Common conditions, including allergies, infections, and parasitic diseases, drive greater demand for dermatological treatments. A study conducted in Ilhéus, Bahia, revealed that 62.3% of dogs were affected by Tunga penetrans, a parasitic skin disease. Key risk factors included semi-restricted living environments and exposure to sandy areas, while frequent clinical manifestations included edema and hyperkeratosis. This research highlights the high prevalence of tungiasis in the canine population and underscores the importance of targeted interventions in regions with substandard living conditions.

Market Segmentation

Drugs Insights

The veterinary antifungal drugs segment is the highest contributor to the market and is expected to grow at a CAGR of 9.62% during the forecast period. Animal skin conditions are primarily treated with several antifungal medications. Growing public awareness of effective and improved treatment options will fuel the segment's expansion. These medications are widely accessible over the counter and effective for treating various skin conditions. Numerous companies produce antibacterial medications for pets and livestock. Animals like dogs, cats, equines, and poultry are the primary consumers of antifungal medications.

Animal Type Insights

The small animal segment is the highest contributor to the market and is expected to grow at a CAGR of 9.44% during the forecast period. It is anticipated that rising pet ownership will hasten market expansion. Additional divisions into distinct categories are made for cats, dogs, horses, and other animals. The dog segment is anticipated to hold the largest market share because so many products are available for treating dogs. The rising demand for animal protein and the prevalence of parasitic diseases in livestock animals are anticipated to drive the market for veterinary dermatology medications. Animals with atopic dermatitis are becoming more common, significantly impacting the need for new veterinary medications.

End Users Insights

The veterinary hospital segment is the highest contributor to the market and is expected to grow at a CAGR of 9.71% during the forecast period. The segment is likely to grow due to the rise in healthcare pharmacies. Furthermore, animal owners favor the diagnostic approach for any treatment or disease screening regarding the rehabilitation of domestic pets or farm animals. Hospital pharmacies, therefore, have a commanding market share because they are the primary locations where prescribed medications are bought. Veterinary hospitals are facilities for the routine care of livestock, pets, small animals, and birds, including immunization, vaccination, artificial insemination, surgical intervention, and more.

List of key players in Veterinary Dermatology Drugs Market

1. Bayer HealthCare Animal Health Inc. (U.S.)
2. Boehringer Ingelheim Vetmedica, Inc.(U.S.)
3. Ceva(France)
4. Zoetis Inc.(U.S.)
5. Elanco(U.S.)
6. IDEXX Laboratories(U.S.)
7. Boehringer Ingelheim International GmbH. (France)
8. Vetoquinol S.A.(France)
9. Virbac(France).

To get more findings about this report Download Market Share

Recent Developments

• June 2025: The FDA has approved the first generic version of cefovecin sodium injection for the treatment of skin infections in dogs and cats. This development is expected to provide veterinarians with a more affordable alternative for treating these common conditions.
• June 2025: The European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for NUMELVI™, a second-generation Janus Kinase (JAK) inhibitor for the treatment of pruritus associated with allergic and atopic dermatitis in dogs. This is a significant step toward a new treatment option for a major canine skin condition.